Karyopharm Reports First Quarter 2024 Financial Results and ...

Applied Therapeutics Reports First Quarter 2024 Financial Results

Net loss for the first quarter of 2024 was $83.9 million, or $0.67 per basic and diluted common share, compared to a net loss of $10.1 million, ...

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial ...

NEWTON, Mass., Feb. 22, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering ...

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing ...

Taking a look back first, we see that the company's revenues underwent some rampant growth over the last 12 months. Although, its longer-term ...

Press Releases - Investor Relations | Karyopharm Therapeutics

May 9, 2019. Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress · May 8, 2019. Karyopharm to Participate in Upcoming ...

Karyopharm Reports First Quarter 2022 Financial Results and ...

XPOVIO Commercial Performance · Achieved U.S. net product revenue for the first quarter of 2022 of $28.3 million, a 30% increase compared to the ...

Press Releases - Investor Relations | Karyopharm Therapeutics

(Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2017 and... May 3, 2017. Karyopharm and Anivive ...

Press Releases - Investor Relations | Karyopharm Therapeutics

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – – ...

Opus Genetics (IRD) Competitors and Alternatives 2024 - MarketBeat

IRD vs. The Competition ; Market Cap, $29.85M · $6.80B ; Dividend Yield, N/A, 8.02% ; P/E Ratio, -1.05, 5.39 ; Price / Sales, 1.57, 417.78 ...

Press Releases - Investor Relations | Karyopharm Therapeutics

– Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by ...

Press Releases - Investor Relations | Karyopharm Therapeutics

Apr 27, 2017. Karyopharm to Report First Quarter 2017 Financial Results on May 4, 2017 · Apr 25, 2017. Karyopharm Therapeutics Announces Pricing of Public ...

Press Releases - Investor Relations | Karyopharm Therapeutics

NEWTON, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will report first quarter 2020 financial ...

Believers in the Extraordinary | Karyopharm

November 5, 2024. Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress · November 1, 2024. Karyopharm Therapeutics ...

Press Releases - Investor Relations | Karyopharm Therapeutics

(Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2018 and... May 7, 2018. Karyopharm Therapeutics ...

Press Releases - Investor Relations | Karyopharm Therapeutics

(Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of... May 3, 2018. Karyopharm to Report First Quarter ...

Press Releases - Investor Relations | Karyopharm Therapeutics

(Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2021 financial ...

Press Releases - Investor Relations | Karyopharm Therapeutics

Karyopharm Therapeutics Reports First Quarter Financial Results for 2014. NATICK, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq ...

Press Releases - Investor Relations | Karyopharm Therapeutics

Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress. -- FDA Extends Review Period for Selinexor ...

Karyopharm Reports Second Quarter 2023 Financial Results and ...

Achieved U.S. net product revenue for the second quarter of 2023 of $28.5 million, compared to $29.0 million U.S. net product revenue in the ...

Karyopharm Reports Fourth Quarter and Full Year 2022 Financial ...

"In 2022, Karyopharm delivered strong financial performance with a 22% increase in U.S. XPOVIO net product revenue, coupled with significant ...

KPTI Q3 2024 Earnings Presentation

These and other risks are described under the caption "Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended June 30 ...